Skip to main content


Oligonucleotide Synthesis, Modification and Purification Services | Industry Analysis | Market Size | 2030 Post the marketing of Vitravene®, the first antisense oligonucleotide-based therapy to receive approval (in 1998), various stakeholders have undertaken multiple research initiatives to verify the potential of oligonucleotides as therapeutic agents